Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia
Can Urol Assoc J
.
2017 May;11(5):E237-E239.
doi: 10.5489/cuaj.4316.
Epub 2017 May 9.
Authors
Gregory W Hosier
1
,
Naji J Touma
1
Affiliation
1
Department of Urology, Queen's University, Kingston, ON, Canada.
PMID:
28503240
PMCID:
PMC5426947
DOI:
10.5489/cuaj.4316
No abstract available